In Luxembourg, molecular agriculture company Moolec Science SA and Bioceres Group Limited have announced an all-stock, business combination agreement.
Subject to the terms and conditions of the BCA, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC, and Gentle Technologies Corp, resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities.
“The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident,” said Federico Trucco, Bioceres Group’s board member and CEO of Bioceres Crop Solutions Corp, in a press statement. “Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability.”
Following the closing of the deal, Moolec will become “uniquely positioned” in the agricultural value-chain, with validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec’s new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.
Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon. Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait. Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.
The deal is expected to close during the second quarter of 2025.